Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PHRM 845 Exam 4 > Pharmacotherapy of Schizophrenia > Flashcards

Pharmacotherapy of Schizophrenia Flashcards

(47 cards)

Start Studying
1
Q

Key features that define psychotic disorders

A
  1. Delusions: fixed false beliefs that are not amenable to change even with conflicting evidence
  2. Hallucinations-perception-like experiences that occur without external stimulus
  3. Disorganized thinking and speech-switching from one topic to another, unrelated answers to questions
  4. Disorganized or abnormal motor behavior
  5. Negative symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Disease course in Schizophrenia

A

Onset late adolescence to early adult

Men-late teens, early 20s

Women–late 20s, early 30s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Link to Substance Use

A

Smoking is associated with induction of 1A2, not due to nicotine, but because of hydrocarbons produced and inhaled, which decreases the serum concentration of 1A2 substrate antipsychotics (olanzapine, asenapine, clozapine, loxapine)

Marijuana, cocaine, and amphetamine use can hasten the onset of schizophrenia, exacerbate symptoms, adn reduce time to relapse

Substance use treatment can be successfully achieved along with mental health treatment with schizophrenia, should be undertaken at the same time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Antipsychotic Drug Therapy overview

A

Doses per day

Side effects: what will patients tolerate? What are their other disease states?

Previous drug therapy: success or failure? Do family members have this disease?

Cost of drug therapy

Concomitant drug therapy

Need for monitoring: labs? weight? ECG?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Antipsychotic Drug Selection

A

Oral antipsychotic drug therapy is generally considered first-line, unless the patient presents with reasons to consider IM depot drug therapy first

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Typical antipsychotics

A

Older agents–primarily D2 receptor antagonists

Efficacy for positive symptoms is similar to atypical antipsychotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Typical antipsychotics clinical pearls

A

Haloperidol is most commonly used–routine PRN

More EPS with high potency typical–and atypical antipsychotics risperidone and paliperidone

Are very effective for treating the positive symptoms, but are likely to worsen negative and cognitive symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Partial agonists

A

“stabilize” dopamine transmission–not too much, not too little

Associated with more akathisia than other antipsychotics

Approved for adjunct treatment in depression so all have boxed warning for suicidal thoughts/behavior

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Aripiprazole

A

Partial Agonist

2D6 and 3A4 substrate

Moderate akathisia

Low weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Brexpiprazole

A

Partial agonist

2D6 and 3A4 substrate

Moderate akathisia

Low-moderate weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cariprazine

A

Partial agonist

3A4 substrate

Moderate akathisia

Low-moderate weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Asenapine

A

Sublingual and patch formulations

1A2 substrate

QTc prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clozapine

A

1A2 substrate

Boxed warnings: neutropenia, orthostasis, bradycardia, syncope, seizures, myocarditis, cardiomyopathy

Side effects: sedation, weight gain, constipation, hypersalivation, dry mouth, GI hypomotility with obstruction risk

QTc prolongation

REMS: monitoring timelines weekly x 6 months, biweekly x 6 months, then every 4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Olanzapine

A

1A2 substrate

Significant weight gain and sedation

High risk metabolic syndrome

DRESS warning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Quetiapine

A

3A4 substrate

QTc prolongation

Weight gain and sedation

Boxed warning for suicidal ideation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Asenapine Transdermal Patch

A

Secuado

Apply 1 patch q24hrs, rotate patch site to minimize application site reactions

Warning for QTc prolongation

UGT and 1A2 substrate–reduce dose of patch if given with strong 1A2 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Olanzapine/Samidorphan

A

Lybalvi

Samidorphan is an opioid antagonist with preferential activity at the mu opioid receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Iloperidone

A

High risk for orthostasis and syncope

QTc prolongation

2D6 substrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Lurasidone

Study These Flashcards
A

3A4 substrate

Higher risk for akathisia

Warning for suicidal thoughts

Adjunct for bipolar depression

Taken with food (350 calories) to increase bioavailability

20
Q

Ziprasidone

Study These Flashcards
A

QTc prolongation

DRESS warning

Take with food to increase absorption

3A4 substrate (1/3) and aldehyde oxidase (2/3) (less worry for P450 interactions)

21
Q

Risperidone

Study These Flashcards
A

2D6 substrate

EPS, hyperprolactinemia, weight gain, sedation, orthostasis

22
Q

Paliperidone

Study These Flashcards
A

Renally-eliminated–dose adjustments in renal impairment

Similar side effects with risperidone

QTc prolongation

23
Q

Lumateperone

Study These Flashcards
A

Low risk for weight gain or metabolic side effects

Low risk for EPS or akathisia

3A4 substrate

24
Q

Pimavanserin

Study These Flashcards
A

Approved for the treatment of hallucinations or delusions in a patient with PD

Inverse agonist and antagonist at the serotonin (5HT) 2A

3A4 substrate

25
Warnings for all antipsychotics
Boxed warning: Increased risk of death in elderly patients treated with antipsychotics for dementia with related behaviors Metabolic adverse effects EPS Risk of somnolence, postural hypotension, and motor and/or sensory instability increases the risk for falls Fall risk assessment should be performed for patients taking other medications or having other disease states that also have a fall/fracture or hypotension risk
26
Haloperidol Injection
Given every 4 weeks Load: 20 times oral dose Maintenance: 10 times oral dose If only use maintenance may need oral overlap Oil-based--Z-track
27
Risperdal Consta
risperidone Must supplement with oral risperidone (or another antipsychotic) for the first few weeks of treatment (week 4)
28
Perseris
risperidone Abdominal subcutaneous injection 3A4 inducers: use 120 mg dose or may need oral supplementation
29
Rykindo
risperidone Every 2 week IM injection Oral overlap is shorter than Risperdal Consta (7 days vs. 21 days) Gluteal injection only
30
Uzedy
Abdominal or upper arm subcutaneous injection Given once monthly for every 2 months
31
Invega Sustenna
paliperidone Loading dose, then booster, then every 4 weeks (starting 5 weeks after loading injection) Initial loading dose and booster doses must be given in deltoid to improve absorption consistency If loading dose strategy followed, no need for oral overlap antipsychotic treatment May require dose adjustment in moderate to severe renal impairment
32
Invega Trinza
May be initiated for a patient who has been on a stable monthly IM injection of Invega Sustenna, at least 4 stable Invega Sustenna doses Recommended to be given deltoid; gluteal administration results in a lower Cmax Not recommended if CrCl < 50 mL/min
33
Invega Hafyera
May be initiated after stable Invega Sustenna for 4 months or stable Invega Trinza after one 3-month dose Gluteal injection only
34
Zyprexa Relprevv
olanzapine PDSS-post-dose delirium sedation syndrome
35
Abilify Maintena
aripiprazole Must overlap with oral aripiprazole for at least 14 days after first injection Deltoid or gluteal injection
36
Abilify Maintena Dose adjustments for P450 interactions
If taking 2D6 or 3A4 inhibitors or 3A4 inducers for more than 14 days as concomitant therapy
37
Abilify Asimtufii
Every-2-month dosing Gluteal injection only continue oral aripiprazole for 2 weeks after first injection
38
Aristada
aripiprazole lauroxil overlap with oral aripiprazole for 3 weeks after the first injection
39
Aristada Initio
Developed to avoid need for 21-day oral overlap of antipsychotic Avoid in patients who are 2D6 poor metabolizers or with strong 3A4 or 2D6 inhibitors
40
Immediate release Antipsychotic Injections/Psychiatric Emergencies
Haloperidol, chlorpromazine, fluphenazine are used, haloperidol most commonly Olanzapine immediate release IM--CANNOT be given at the same time as a benzodiazepine immediate release injection--boxed warning for respiratory depression Loxapine for inhalation (Adasuve)
41
Clinical treatment Strategies for EPS
Acute Dystonia: IM anticholinergic NOW dose (benztropine 2 mg, diphenhydramine) Drug-induced Parkinson's: Oral anticholinergic (benztropine, trihexyphenidyl, diphenhydramine) Akathisia: Beta blocker (propranolol 1st line), Benzodiazepine-- usually lorazepam Tardive Dyskinesia: VMAT inhibitors
42
VMAT inhibitors
50% reduction in AIMS score for tardive dyskinesia
43
Valbenazine
2D6/3A4 substrate QTc prolongation
44
Deutetrabenazine
2D6 substrate QTc prolongation
45
Neurologic Malignant Syndrome
Life-threatening--IS a medical emergency Hyperpyrexia, tachycardia, labile blood pressure Muscle rigidity--elevated (significantly) CK, myoglobinuria Treatment is supportive Future antipsychotic use is NOT contraindicated
46
Metabolic Averse Effects
Hyperglycemia, hyperlipidemia, hypertension clozapine=olanzapine > quetiapine=risperidone=paliperidone=asenapine=iloperidone=cariprazine=brexpiprazole> ziprasidone=lurasidone=aripiprazole
47
Metabolic monitoring
Personal/family hx Weight Waist circumference BP FPG/A1c Fasting lipids

PHRM 845 Exam 4 (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions